The MYCN protooncogene is involved in the control of cell proliferation, differentiation, and survival of neuroblasts. Deregulation of MYCN by gene amplification contributes to neuroblastoma development and is strongly correlated to advanced disease and poor outcome, emphasizing the urge for new therapeutic strategies targeting MYCN function. The transcription factor N-Myc, encoded by MYCN, regulates numerous genes together with its partner Max, which also functions as a cofactor for the Mad/Mnt family of Myc antagonists/transcriptional repressors. We and others have previously reported that IFN-; synergistically potentiates retinoic acid (RA) -induced sympathetic differentiation and growth inhibition in neuroblastoma cells. This study shows that combined treatment of MYCN-amplified neuroblastoma cells with RA+IFN-; down-regulates N-Myc protein expression through increased protein turnover, up-regulates Mad1 mRNA and protein, and reduces N-Myc/Max heterodimerization. This results in a shift of occupancy at the ornithine decarboxylase N-Myc/Mad1 target promoter in vivo from N-Myc/Max to Mad1/Max predominance, correlating with histone H4 deacetylation, indicative of a chromatin structure typical of a transcriptionally repressed state. This is further supported by data showing that RA+IFN-; treatment strongly represses expression of N-Myc/Mad1 target genes ornithine decarboxylase and hTERT. Our results suggest that combined IFN-; and RA signaling can form a basis for new therapeutic strategies targeting N-Myc function for patients with high-risk, MYCN-amplified neuroblastoma. [Mol Cancer Ther 2007;6(10):2634 -41] 
Introduction
Neuroblastoma originates from sympathetic neuroblasts of the peripheral nervous system and is one of the most common solid childhood tumors, accounting for 7% to 10% of the childhood cancers and around 15% of childhood cancer deaths (1) . Twenty-two percent of neuroblastomas and f40% of advanced stage cases exhibit amplification of the MYCN protooncogene, a condition that is strongly correlated with advanced disease, drug resistance, and poor outcome (1 -3) . Targeting expression of MYCN to neuroectodermal cells has been reported to cause neuroblastoma in transgenic mice, further suggesting a crucial role of deregulated MYCN in neuroblastoma development (4) . Moreover, ectopic overexpression of MYCN in neuroblastoma cell lines lacking MYCN aberrations results in enhanced growth potential and tumorigenicity, whereas antisense MYCN experiments have the opposite effect (2, 5) .
MYCN is a member of the MYC gene family, including MYC, MYCN, and MYCL. All MYC family genes stimulate cell growth and proliferation, counteract terminal cell differentiation, sensitize cells to apoptosis in a similar fashion, and are all involved in the development of various types of tumors when deregulated (for review, see 6 -8) . The MYC family is a subfamily of the basic region/helixloop-helix/leucine zipper class of transcription factors which bind E-box DNA recognition sequences in promoters of target genes by heterodimerization with the obligatory partner Max, thereby activating transcription (for review, see refs. 6 -8) . However, Max also forms heterodimers with the Mad/Mnt family of basic region/ helix-loop-helix/leucine zipper proteins, including Mad1, Mxi1, Mad3, Mad4, and Mnt/Rox, as well as with Mga, thereby forming alternative E-box -binding complexes (6, 9 -11) . Mad/Mnt proteins repress c-Myc -induced transcription, cell proliferation, and transformation and are therefore considered to be antagonists of Myc. To repress transcription, Mad/Mnt proteins interact with the repressor protein Sin3, which is part of repressor complexes containing histone deacetylases (6, 9 -11) . c-Myc, on the other hand, activates transcription at least in part by recruiting histone acetyltransferases complexes to target promoters through interaction with the cofactor/ adaptor protein TRRAP (6 -8) . Modulation of chromatin structure is therefore one way for both the Myc and Mad/ Mnt family proteins to regulate transcription. Recent reports suggest that c-Myc may control up to 10% to 15% of all genes in the genome, thereby affecting numerous fundamental cellular processes, including cell cycle, cell growth, protein synthesis, metabolism, apoptosis, senescence, differentiation, genomic stability, angiogenesis, adhesion, etc. (6 -8, 12) .
Based on the gene expression patterns during development and differentiation and the antagonistic functions of the Myc and Mad family proteins, one current hypothesis suggests that the Myc/Max/Mad network proteins constitute a molecular switch that determines cell fate by regulating an overlapping set of genes. This model is supported by evidence showing that the occupancy of E-box -containing regions of the CYCLIND2 and hTERT target gene promoters in vivo shifts from c-Myc/Max toward Mad1/Max predominance during hematopoietic differentiation, correlating with histone deacetylase recruitment, histone deacetylation, and repression of gene activity (13, 14) . It is still unclear how large fraction of c-Myc target genes are coregulated by the Mad/Mnt family, but both families also seem to control unique sets of genes by interacting with alternative partners that bind non -E-box motifs, such as Miz-1, which is used by c-Myc for repression of certain genes (8, 12, 15, 16) .
The poor outcome of patients with MYCN-amplified neuroblastoma despite intensive therapy has called for development of alternative therapeutic strategies. Studies using mouse models have shown that even temporary inactivation of c-Myc in c-Myc -driven tumors is sufficient for irreversible tumor cell differentiation and growth arrest, or alternatively apoptosis, in both cases resulting in permanent tumor regression (for review, see ref. 17) . Identifying ways of down-regulating the expression or activity of N-Myc or alternatively to up-regulate expression or activity of Mad/Mnt family proteins in MYCN-amplified neuroblastomas could therefore be of potential therapeutic interest. Treatment of neuroblastoma cell lines with retinoic acid (RA) induces neuronal differentiation linked to growth inhibition and is accompanied by reduction of MYCN expression (3, 5) . This raised the question whether ''differentiation therapy'' for neuroblastomas could improve event-free survival, in particular for treatment of minimal residual disease (18) . Indeed, high dose 13-cis RA treatment of patients with high-risk neuroblastoma after autologous bone marrow transplantation showed encouraging results in a phase III clinical trial (19) . We and others have previously reported that IFN-g strongly enhances RA-induced differentiation and growth inhibition of MYCN-amplified human neuroblastoma cell lines in vitro (20 -23) and, synergistically with RA, represses their tumor growth in nude mice (21) . The purpose of the present study was to determine whether combined RA+IFN-g treatment affects expression and/or activity of members of the Myc/Max/Mad network in MYCN-amplified neuroblastoma cells. We show that RA+IFN-g down-regulates N-Myc through increased protein turnover, up-regulates Mad1 expression, and reduces N-Myc/Max heterodimerization. This alters N-Myc/Mad1 occupancy at a target promoter in vivo in favor of Mad1, resulting in strong repression of N-Myc target genes. These results suggest that combination therapy with IFN-g could be of interest for treatment of patients with neuroblastoma harboring MYCN amplification.
Materials and Methods

Cell Cultures and Induction of Differentiation
The human neuroblastoma cell lines LA-N-5 and IMR-32 were cultured in RPMI 1640 and DMEM, respectively, supplemented with 10% FCS and antibiotics. Cells plated the day before at 1 Â 10 5 cells per 6-cm dish were induced to differentiate in medium containing 1 Amol/L all-trans RA (Sigma), 100 to 200 units/mL IFN-g (generously provided by Dr. G.R. Adolf, Ernst-Boehringer Institute) or their combination. Cell number and viability were determined by trypan blue exclusion. The morphology of the cells was evaluated under a phase contrast Zeiss microscope (Carl Zeiss), and photographs were taken through an Olympus phase contrast microscope. The percentage of morphologically differentiated cells was determined by counting at least 100 randomly chosen cells, wherein cells exhibiting neurites at z50 Am were scored as positive. Neurite outgrowth index (24) was defined as the product of the percentage of cells with neurites at z50 Am and the average total neurite length.
Immunoprecipitations and Western Blot Analysis Cell labeling and immunoprecipitation were done as described previously (25) . Briefly, cells were labeled for 50 min in 1.5 mL of methionine (Met) -free RPMI 1640 containing 0.2 mCi of 35 S-Met. For high and low stringency precipitations, cells were lysed in AB and Tris lysis buffer, respectively (25) , and immunoprecipitated with specific antibodies. An equal number of TCA-precipitable counts were used for each sample. The washing procedure for high and low stringency immunoprecipitations has been described (25) . The samples were analyzed on 10% to 15% SDS-PAGE gels. For studies of protein turnover, cells were pulse labeled for 40 min as above, followed by chase in medium containing 1 mmol/L cold Met and 10 Ag/mL cycloheximide. Western blot analysis was carried out as described (25) . The antibodies used for immunoprecipitation were C-19 Mad1 antibodies (Santa Cruz Biotechnology), IG-7 pan-Myc antiserum (25), AB-1 N-Myc antibodies (Oncogene Science), and C-17 Max antibodies (Santa Cruz). Radioactive signals were quantitated with a Phosphor Imager (Bio-Rad).
Quantitative Reverse Transcription^PCR and Northern Blot Analysis
Total RNA (4 Ag) was converted to cDNA with RevertAid M-MuLV reverse transcriptase (Fermenta). Ornithine decarboxylase (ODC) -specific and hTERT-specific primers and probes for reverse transcription -PCR were designed by the software Primer Express (Perkin-Elmer Applied Biosystems). As reference genes, GAPDH, b-ACTIN, and a-TUBULIN were used. Primer sequences are provided upon request. Quantitative PCR reactions were done in triplicates, using the Taqman PCR Core Reagent kit (Applied Biosystems) with the ABI PRISM 7700 Sequence Detector (Perkin-Elmer).
Northern blot analysis was carried out as described (23) . For MAD1, a 1.1-kb NotI/EcoRI fragment from the cDNA clone pVZ1mad (kindly provided by D. Ayer) was used, whereas for MAX, a 540-bp EcoRI fragment from the MAX cDNA clone pVZ1max (kindly provided by R. Eisenman) was used. The probes for MYCN and GAPDH have been described (23) .
Chromatin Immunoprecipitation Assays Cells were lysed and crosslinked with formaldehyde as described (13) . Chromatin DNA was sonicated to an average size of 300 to 500 bp. Immunoprecipitations were carried out in radioimmunoprecipitation assay buffer with the following antibodies: IG0 (preimmune serum), antiMax, anti -N-Myc, and anti-Mad1 from Santa Cruz and anti -acetyl histone H4 from Upstate. Immunoprecipitates were collected with protein G -sepharose beads, washed, and eluted in TE, 1% SDS. Purified DNA samples were analyzed by quantitative PCR as above using primers specific for an E-box -containing regulatory region of the ODC gene (7) . As control, a non -E-box region of the FasL was used. Quantitative PCR primer sequences are provided upon request.
Results
Combined RA+IFN-; Treatment Reduces N-Myc and Induces Mad1 Expression Correlating with Robust Differentiation in MYCN-Amplified Neuroblastoma Cells IFN-g has been reported to potentiate RA-induced differentiation in MYCN-amplified neuroblastoma cell lines (20 -23) . To investigate whether such cooperative effects correlate with regulation of N-Myc and/or Mad1 protein expression, we used IMR-32 and LA-N-5 cells, both with very high copy numbers of MYCN (3) and very high N-Myc expression ( Supplementary Fig. S1 ). 6 Supplementary Table S1 6 shows that IFN-g enhanced RAinduced differentiation measured as the percentage of morphologically differentiated cells with neurites as reported previously (23) . Furthermore, in contrast to the effect of each agent alone, complete growth arrest rather than only growth retardation was induced by their combination (data not shown; Supplementary Table S1;   6 ref. 23) .
A substantial decrease of N-Myc protein expression, as determined by immunoprecipitation of 35 S-Met -labeled cell lysates, was observed in both cell lines in response to the combination RA+IFN-g, whereas RA alone led only to a modest reduction in LA-N-5 cells (Fig. 1A and B) , as quantitated in Fig. 1D (top) . This is in agreement with previous reports on MYCN mRNA expression in LA-N-5 cells (22, 23) . In contrast, only a slight reduction in MYCN mRNA expression was observed in IMR-32 cells in response to RA+IFN-g treatment ( Fig. 1C and D; ref. 23 ).
RA and RA+IFN-g treatment increased the expression of Mad1 in IMR-32 cells (Fig. 1B and D) . In contrast, in LA-N-5 cells, RA+IFN-g and IFN-g alone increased Mad1 expression ( Fig. 1A and D) . This may suggest that RA-induced or IFN-g -induced signals alone may regulate Mad1 expression differently in different neuroblastoma tumors. The reason for this difference is unclear but may be due to deregulation in tumor cells of one or the other of the diverse signaling pathways that activate Mad1 expression. The combination of RA+IFN-g is therefore more likely to result in Mad1 induction than either treatment alone. The expression of MAD1 mRNA, analyzed in IMR-32 cells (Fig. 1C and D) , followed the same pattern of expression, suggesting that Mad1 is regulated at the level of transcription in response to signaling, as reported previously in other cells types (9 -11). We did not have access to antibodies of high enough quality for protein analysis of Mxi1, Mad3, Mad4, or Mnt. Northern blot analysis, however, did not reveal increased expression of the corresponding genes in response to treatment with RA, IFN-g or their combination (data not shown). No major changes in Max protein and mRNA expression were observed after the different treatments (Fig. 1) .
In summary, the cooperative effects of RA+IFN-g on differentiation and growth arrest correlated with decreased N-Myc and increased Mad1 expression. RA+IFN-; Costimulation Induces Increased N-Myc ProteinTurnover Interestingly, Fig. 1 suggests that RA+IFN-g downregulates N-Myc protein expression posttranscriptionally, because the steady-state level of MYCN mRNA was only slightly affected in IMR-32 cells. We therefore continued to explore this phenomenon in IMR-32 cells. To investigate whether RA+IFN-g affects the turnover rate of N-Myc, cells were pulse labeled with 35 S-Met, followed by chase, in excess cold Met, after which remaining labeled N-Myc was assessed at various time points. Figure 2A shows that RA+IFN-g, but not either treatment alone, increased the speed of N-Myc protein degradation from f40 min to 15 to 20 min half-life, as quantitated in Fig. 2B .
This suggests that RA+IFN-g affects the N-Myc/Max/ Mad network at three levels by decreasing MYCN mRNA (LA-N-5 cells), increasing MAD1 mRNA, and increasing the rate of N-Myc protein turnover.
IFN-; Costimulation Results in Reduced N-Myc/Max Complex Formation
Because N-Myc requires heterodimerization with Max for its activity, we next studied whether N-Myc/Max heterodimerization were altered in response to treatment in 6 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). IMR-32 cells. As shown in Fig. 3 , RA+IFN-g, and to lesser extents RA and IFN-g alone, significantly reduced the concentration of N-Myc/Max heterodimers (15% of untreated cells; Fig. 3B ) beyond the effect on total N-Myc expression (60% of untreated cells; Fig. 1B and D) . These results are in agreement with earlier studies in monocytic cells, wherein IFN-g treatment in combination with 12-Otetradecanoylphorbol-13-acetate was shown to destabilize Myc/Max heterodimers (25) . Unfortunately, we were not able to measure Mad1/Max complexes in the neuroblastoma cells because they were below the level of detection in this assay. The slight reduction in total Max protein levels after the treatments was found to be not significant (Fig. 3) .
We conclude that RA+IFN-g in particular decreased the level of N-Myc/Max complexes in the IMR-32 cells, in part via increased N-Myc turnover and possibly also via other posttranslational effects on N-Myc/Max complex formation and/or stability. We next investigated N-Myc, Mad1, and Max occupancy of the ODC gene, a target for both N-Myc and Mad (26 -28) , in vivo by performing quantitative chromatin immunoprecipitation assays. As shown in Fig. 4 , a-N-Myc and a-Max antibodies readily immunoprecipitated an E-box -containing fragment of the ODC promoter from unstimulated IMR-32 cells, whereas only a weak signal was obtained using a-Mad1 antibodies. Neither preimmune control antibodies nor any immunoprecipitation of the non -E-box, but MEF2-binding, region of the Fas ligand gene, used as a reference, gave signals above background. After RA+IFN-g treatment, the N-Myc signal decreased to f40% of untreated cells, whereas binding of Mad1 increased f2.5-fold. RA alone also decreased and increased N-Myc and Mad1 associations with promoter, respectively, but to lesser extents. The association of Max did not change significantly after the treatments. RA and RA+IFN-g -induced differentiation also resulted in a decreased acetylation of histone H4 in the same region of the promoter, indicative of alteration of the chromatin structure into a more repressed state during the process, a hallmark of decreased Myc and/or increased Mad activity at target promoters.
In conclusion, our results suggest that the ODC promoter occupancy shifted from N-Myc/Max predominance in untreated cells toward Mad1/Max predominance after RA+IFN-g -induced and, to a lesser extent, RA-induced differentiation, resulting in a more condensed chromatin structure at the promoter.
The ODC and hTERT N-Myc/Mad1 Target Genes Are Repressed in Response to RA+IFN-; Costimulation
We next investigated whether the treatments affect the expression of N-Myc/Mad1 target genes. mRNA expression of the ODC and hTERT target genes of N-Myc and Mad (14, 26 -30) was therefore measured in IMR-32 cells by quantitative reverse transcription -PCR. As shown in Fig. 5 , ODC and hTERT expression was reduced to various degrees in response to RA or IFN-g alone. However, RA+IFN-g in combination led to strong repression of ODC and hTERT expression to around 20% of control.
Taken together, these results suggest that the combined treatment with RA+IFN-g regulates expression of N-Myc and Mad1, as well as N-Myc/Max heterodimerization, resulting in a shift from N-Myc/Max toward Mad1/Max occupancy at N-Myc/Mad1 target promoters. This in turn results in altered chromatin structure and transcriptional repression. 
Discussion
IFN-g is reported to potentiate RA-induced growth retardation and differentiation in several MYCN-amplified neuroblastoma cell lines (20 -23) . We show here that this correlates with reduced and increased expression of N-Myc and Mad1, respectively. In IMR-32 cells, the drop in N-Myc protein in response to RA+IFN-g is much more pronounced than the slight reduction in MYCN mRNA expression, and we show that this is the result of increased turnover of the N-Myc protein. Recently, we have made similar observations in v-myc -transformed U-937 monoblastic cells, wherein combined IFN-g and 12-O-tetradecanoylphorbol-13-acetate treatment results in ubiquitin/ proteasome-mediated degradation of v-Myc. 7 Elucidating the mechanism by which combined IFN-g treatments increase Myc turnover will require further investigation. In contrast, Mad1 seems to be regulated at the mRNA level, as has been shown in other cell systems (9 -11) . In addition, RA+IFN-g treatment and, to a lesser extent, RA and IFN-g alone seemed to regulate N-Myc/Max heterodimerization, suggesting that these signals regulate N-Myc activity posttranslationally at different levels. This is also reminiscent of the situation in v-myc -transformed U-937 cells, wherein 12-O -tetradecanoylphorbol-13-acetate+IFN-g treatment inhibits v-Myc DNA binding and heterodimerization with Max (25, 31) . Our present results further show that N-Myc/Max complexes were exchanged by Mad1/ Max complexes at the ODC target promoter in RA+IFN-gdifferentiated and, to a lesser extent, RA-differentiated cells. This correlated with deacetylation of histone H4 in the same region of the promoter, suggesting that RA and RA+IFN-g induces a repressive chromatin state by increased recruitment of histone deacetylases and/or reduced recruitment of histone acetyltransferases through Mad1 and N-Myc, respectively. These results are in good agreement with previously reported exchanges of c-Myc/ Max to Mad1/Max complexes on the CYCLIND2 and hTERT target promoters during differentiation of human myeloid HL60 cells (13, 14) . Finally, our results show that RA+IFN-g represses expression of the N-Myc/Mad1 target genes ODC and hTERT much more efficiently than either agent alone, thus demonstrating a functional consequence of the cooperative signaling. Our results suggest that both the down-regulation of N-Myc and the up-regulation of Mad1 in response to RA+IFN-g treatment contribute to this shift in N-Myc/Max/Mad1 promoter occupancy and repression of promoter activity. Because RA alone accomplished H4 deacetylation at least as well as RA+IFN-g, it is likely that also other aspects of Myc-regulated transcription are affected by the combined treatment.
Apart from the N-Myc/Max/Mad network, it is likely that RA and IFN-g also affects other regulators that may contribute to the differentiation of MYCN-amplified neuroblastoma cells. For instance, the cyclin-dependent kinase inhibitor p21Cip1 is up-regulated by IFN-g via the Janusactivated kinase -STAT pathway in various cells (32) . In addition, both p21Cip1 and p27Kip1 have been shown to be up-regulated during RA treatment of neuroblastoma and (33 -36) . Interestingly, Mad1 and p27Kip1 have been shown to cooperate in promoting granulocytic differentiation and in regulating self-renewal/ differentiation of hematopoietic stem cells (37, 38) . IFN-g was recently shown to restore promyelocytic leukemia protein nuclear body formation in neuroblastoma cells (39) . Because promyelocytic leukemia protein interacts with Sin3-containing corepressor complexes and is required for the transcriptional repressor function of Mad1 (40) , promyelocytic leukemia protein may contribute to the observed repression of N-Myc/Mad1 target genes in response to IFN-g costimulation once Mad1/Max complexes have bound to their target promoters. Furthermore, recent reports suggest that promyelocytic leukemia protein may also regulate c-Myc function (41, 42) .
The concept of ''differentiation therapy'' for cancer has gained considerable interest in recent years. Today, RA is used successfully in therapy for patients with acute promyelocytic leukemia (43) and treatment of neuroblastoma patients with high-dose 13-cis RA treatment after myeloablative therapy and autologous bone marrow transplantation have shown encouraging results (1, 19, 44) . The synergistic effects of RA+IFN-g for differentiation of MYCN-amplified neuroblastoma cells, shown in vitro (20, 22, 23) as well as in vivo by inhibition of tumor formation of LA-N-5 neuroblastoma cells injected in nude mice (21) , are further substantiated here by the demonstration of direct effects on the N-Myc/Max/Mad1 network. This suggests that RA+IFN-g combination therapy may be of therapeutic value for treatment of patients with MYCNamplified neuroblastomas. In this respect, it is encouraging that even transient inactivation of c-Myc in c-Myc -driven murine tumors is sufficient for permanent tumor regression (17) . The fact that both RA and IFN-g have been used already as single agents in clinical trials for neuroblastoma therapy (19, 45) and that their combination synergistically inhibits neuroblastoma tumor growth as xenografts in mice (21) should facilitate this approach. IFN-g acts synergistically with a number of signal pathways, for instance, in the induction of apoptosis by Fas-L and TRAIL in neuroblastoma cells (46 -49) . It would be interesting to study if IFN-g can cooperate also with other retinoids, such as fenretinide (4HPR), which, unlike at-RA and 13-cis-RA, induces apoptosis rather than differentiation and has also been used in clinical trials in neuroblastoma (44) . Although the clinical use of RA and IFN-g may also have limitations due to side effects and development of drug resistance, insights into the precise molecular mechanisms by which IFN-g, RA, and other agents cooperatively regulate the N-Myc/ Max/Mad1 network will be essential for the development of novel therapeutic strategies, including new drug design for treatment of patients with high-risk neuroblastoma with MYCN amplification. 
